Home Illustration

NX-13 is an oral NLRX1 agonist for the treatment of Ulcerative Colitis and Crohn’s Disease. NX-13’s bimodal mechanism of action aims to decrease reactive oxygen species and oxidative stress, while decreasing pro-inflammatory signals.

We are committed to
the development of
first-in-class, oral
therapeutics for
patients with
autoimmune disease

Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease.

Landos was established as an incredibly productive research engine, with a current portfolio of two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space, including our clinical stage program NX-13 for Ulcerative Colitis and Crohn’s Disease.

View More about Landos Biopharma

Reprogramming Immune Responses in Autoimmune Disease

Using its advanced AI platform to explore immune cell activity and metabolic function, Landos has identified novel pathways including NLRX1 and PLXDC2. The NLRX1 pathway works to decrease reactive oxygen species and downregulate effector immune responses.  The PLXDC2 pathway leads to the production of IL-10 and prevention of oxidative stress when activated.

View More about Immunometabolic Pathways

Aiming to Bring Safer,
More Effective
Therapies to Patients
with IBD

For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Landos’ therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.

At Landos Biopharma, our mission is to
be bold and uncover new mechanisms of
treating autoimmune disease.